David R. Bauer
Lawyers
Filters
Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen
We are advising Cellular Biomedicine Group on the transaction
IDEAYA Biosciences $201 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Gamida Cell $23 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
AVITA Medical at-the-market offering
The stock is listed on the Nasdaq Global Market
InflaRx follow-on offering
The shares are listed on the Nasdaq Global Market
Medtronic Global Holdings $2 billion notes offering
The investment-grade offering comprises two tranches of notes
Intercept Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Trimble $800 million notes offering
The 6.1% notes are due 2033
Revolution Medicines $345 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Stanley Black & Decker $750 million notes offering
The investment-grade notes are due 2026 and 2028